Professor Adrian Brunt's Outputs (4)

Dose escalated simultaneous integrated boost radiotherapy for women treated by breast conservation surgery for early breast cancer: 3-year adverse effects in the IMPORT HIGH trial (CRUK/06/003) (2018)
Presentation / Conference
Coles, C., Griffin, C., Kirby, A., Haviland, J., Titley, J., Benstead, K., …Yarnold, J. (2018, December). Dose escalated simultaneous integrated boost radiotherapy for women treated by breast conservation surgery for early breast cancer: 3-year adverse effects in the IMPORT HIGH trial (CRUK/06/003). Presented at 2018 San Antonio Breast Cancer Symposium, San Antonio, Texas, USA

Meeting abstract (Abstract GS4-05 from 2018 San Antonio Breast Cancer Symposium; December 4-8, 2018; San Antonio, Texas).

AZD5363 plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (PAKT): A randomised, double-blind, placebo-controlled, phase II trial (2018)
Presentation / Conference
Schmid, P., Abraham, J., Chan, S., Wheatley, D., Brunt, M., Nemsadze, G., …Turner, N. C. (2018, June). AZD5363 plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (PAKT): A randomised, double-blind, placebo-controlled, phase II trial. Presented at 2018 ASCO Annual Meeting I, Chicago, IL, USA

Background: The PI3K/AKT signalling pathway is frequently activated in triple-negative breast cancer (TNBC). AZD5363 is a highly-selective, oral, small molecule AKT inhibitor. The PAKT trial investigated the addition of AZD5363 to paclitaxel as 1st-l... Read More about AZD5363 plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (PAKT): A randomised, double-blind, placebo-controlled, phase II trial.

Radioactive Phosphorous (P32) Leukomogenic and Oncogenic Risk Stratification (2018)
Presentation / Conference
Fullagar, A., Sodhi, L., Pillai, S., & Brunt, A. (2018, April). Radioactive Phosphorous (P32) Leukomogenic and Oncogenic Risk Stratification. Paper presented at 58th Annual Scientific Meeting of the British-Society-for-Haematology, Liverpool, UK

Meeting abstract

Benefits in early use of eribulin in metastatic breast cancer: A 7-year UHNM experience (2018)
Presentation / Conference
Yoganayagam, N., Tripathy, A., Exton, S., Rawet, T., Wu, K., Brunt, A., …Jegannathen, A. (2018, March). Benefits in early use of eribulin in metastatic breast cancer: A 7-year UHNM experience. Paper presented at THE 11TH EUROPEAN BREAST CANCER CONFERENCE, Barcelona, Spain

Meeting abstract from 11th European Breast Cancer Conference (EBCC), Barcelona, Spain, Mar 21-23, 2018.